Physician profile
Alejandro Paz
NPI 1760400386
$4,312.00
in general payments reported to CMS, 2019-2025
24 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $543 · 2021: $757 · 2022: $308 · 2023: $271 · 2024: $425 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,765.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $994.80 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $194.06 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $154.54 | 2019-2024 | Veozah |
| Pfizer INC. | $120.19 | 2019-2025 | |
| Abbvie INC. | $120.01 | 2019-2021 | |
| Lilly USA, LLC | $118.84 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Gilead Sciences, INC. | $82.25 | 2025 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $81.20 | 2019-2023 | |
| Biotronik INC. | $76.37 | 2020 | |
| Merck Sharp & Dohme LLC | $74.94 | 2019-2025 | Belsomra, Gardasil 9, Rotateq |
| Amgen INC. | $69.93 | 2019-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $63.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.81 | 2019-2022 | |
| Boston Scientific Corporation | $54.89 | 2025 | Wavewriter Alpha Prime 16 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $52.29 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $46.50 | 2019 | |
| Sanofi Pasteur INC. | $42.19 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $38.56 | 2025 | Rexulti |
| Dexcom, INC. | $35.04 | 2024 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $23.48 | 2024 | |
| Amarin Pharma, INC. | $17.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2020 | |
| Biowound Solutions, INC. | $9.84 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Paz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.